Hepatitis

The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy bemnifosbuvir and ruzasvir in adults with chronic…

Six months of treatment with Kezar Life Sciences‘ candidate zetomipzomib led to biochemical disease remission for adults with treatment-resistant autoimmune hepatitis, enabling them…

Precision Biosciences has been given the go-ahead to expand a Phase 1 clinical trial testing PBGENE-HBV, its gene-editing therapy for chronic hepatitis…

The first patient has been enrolled in ECLIPSE 1, a Phase 3 clinical trial testing Vir Biotechnology’s experimental combination of tobevibart and elebsiran in adults…

Atea Pharmaceuticals plans to launch two parallel Phase 3 trials soon to test its investigational combination therapy of bemnifosbuvir and ruzasvir for people with…

Researchers have discovered a key mechanism that allows the hepatitis B virus (HBV) to infect and persist in liver cells, in a new study…

A program using a telemedicine approach to treat hepatitis C in people with opioid use disorder that resulted in the cure of more than…

A single dose of Precision BioSciences’ investigational gene-editing therapy PBGENE-HBV was well tolerated and showed early signs of antiviral activity among three adults with…

A Phase 2b clinical trial testing AusperBio’s investigational therapy AHB-137 in people with chronic hepatitis B has completed dosing and is now unblinded,…

A virtual clinic for liver diseases, including hepatitis, has begun treating patients. The LiverRight Hepatology Clinic offers same-week video visits to adults who…